Metabolism and pharmacokinetics of the cardiotonic agent piroximone and of its major metabolite in dog

Abstract

1. Piroximone was administered orally (p.o.) and intravenously (i.v.) to male Beagle dog. In vitro, piroximone was incubated with dog liver microsomes.

2. Piroximone was metabolized in vivo to five metabolites (1–5) representing approximately 20% of the total administered dose.

3. The parent drug and its metabolites were totally eliminated in urine.

4. Reduced piroximone (piroximole), representing approximately 10% of the administered dose, was identified as the major metabolic product in vivo.

5. In vitro, piroximone was metabolized by dog liver microsomes to isonicotinic acid (1) and piroximole (4), with the same ratio as in vivo (1:4 = 0·2). The Michaelis-Menten parameters were determined for piroximole formation and were: K_mapp = 733μM and V_{max app} = 232 pmol/mg protein/min.

6. Comparison of the pharmacokinetics of piroximone and piroximole revealed that both compounds were very well absorbed (F = 93 ± 7 and 89 ± 8% respectively), slightly distributed (V_{d app} = 0·78 + 0·04 and 1·02 · 0·09 1/kg p.o., and 0·95 ± 0·05 and 0·76 ± 0·13 1/kg i.v. respectively) and excreted into urine to the same extent (U_Ex = 54·7 ± 1·2 and 53·2 ± 12·6% p.o., and 59·1 ± 5·3 and 51·2±5·7% i.v. respectively), except that the clearance of piroximone was two-fold higher than that observed for piroximole (Cl_± = 7·77 ± 1·35 and 4·12±0·44 ml/min/kg p.o., and 7·68±1·25 and 4·06±0·51 ml/min/kg i.v. respectively).